|
G
|
A2m
|
alpha-2-macroglobulin
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of A2M protein
|
CTD |
PMID:20531411 |
|
NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:154,897,877...154,947,786
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of ABCB1 mRNA; Gemcitabine results in decreased expression of ABCB1 protein
|
CTD |
PMID:35063459 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G
|
Acp3
|
acid phosphatase 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of ACP3 protein
|
CTD |
PMID:20531411 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G
|
Adam17
|
ADAM metallopeptidase domain 17
|
multiple interactions
|
ISO
|
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein]
|
CTD |
PMID:20726858 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:40,872,856...40,920,639
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ADIPOQ protein
|
CTD |
PMID:20531411 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G
|
Afp
|
alpha-fetoprotein
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of AFP protein
|
CTD |
PMID:20531411 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G
|
Agpat2
|
1-acylglycerol-3-phosphate O-acyltransferase 2
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of AGPAT2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
affects response to substance multiple interactions
|
ISO
|
AKT1 protein affects the susceptibility to Gemcitabine [Gemcitabine co-treated with licoricidin] results in decreased phosphorylation of AKT1 protein; [licoricidin co-treated with Gemcitabine] results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:15867245 PMID:29782821 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
multiple interactions decreases expression
|
ISO
|
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of ALDH1A1 protein]
|
CTD |
PMID:20940707 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G
|
Aldh6a1
|
aldehyde dehydrogenase 6 family, member A1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ALDH6A1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:109,809,092...109,829,725
Ensembl chr 6:104,077,979...104,098,656
|
|
G
|
Anapc1
|
anaphase promoting complex subunit 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ANAPC1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:115,850,117...115,930,259
Ensembl chr 3:115,850,185...115,930,273
|
|
G
|
Ank3
|
ankyrin 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ANK3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,602,786...19,086,300
|
|
G
|
Ankrd1
|
ankyrin repeat domain 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ANKRD1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G
|
Antxr1
|
ANTXR cell adhesion molecule 1
|
affects expression
|
ISO
|
Gemcitabine affects the expression of ANTXR1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
|
|
G
|
Apcs
|
amyloid P component, serum
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of APCS protein
|
CTD |
PMID:20531411 |
|
NCBI chr13:87,905,532...87,906,508
Ensembl chr13:85,373,220...85,374,298
|
|
G
|
Apoh
|
apolipoprotein H
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of APOH protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions
|
ISO
|
Gemcitabine binds to and results in decreased activity of AR protein
|
CTD |
PMID:25752796 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G
|
Areg
|
amphiregulin
|
multiple interactions increases expression increases cleavage decreases response to substance
|
ISO
|
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein] Gemcitabine results in increased expression of AREG protein AREG protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:20726858 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:16,972,187...16,981,535
|
|
G
|
Arf1
|
ARF GTPase 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of ARF1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ARNT mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G
|
Atf3
|
activating transcription factor 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ATF3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631
|
|
G
|
Axin2
|
axin 2
|
affects expression
|
ISO
|
Gemcitabine affects the expression of AXIN2 mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr10:94,393,379...94,426,579
Ensembl chr10:93,899,245...93,926,231
|
|
G
|
Axl
|
Axl receptor tyrosine kinase
|
multiple interactions
|
ISO
|
AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]
|
CTD |
PMID:26206560 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:81,265,088...81,296,265
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[alvocidib co-treated with Gemcitabine] results in increased expression of BAX protein; [ICI 118551 co-treated with Gemcitabine] results in increased expression of BAX protein; [Mastic Resin co-treated with Gemcitabine] results in increased expression of BAX protein; [TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein
|
CTD |
PMID:15770523 PMID:17671697 PMID:20523344 PMID:21570961 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of BCL2 protein [alvocidib co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Aminophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [ICI 118551 co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Mastic Resin co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Theophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [Gemcitabine results in decreased expression of BCL2 protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2 protein
|
CTD |
PMID:15476743 PMID:15645133 PMID:15770523 PMID:16929163 PMID:17440100 PMID:20523344 PMID:21570961 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions decreases expression
|
ISO
|
Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2L1 protein Gemcitabine results in decreased expression of BCL2L1 protein
|
CTD |
PMID:15476743 PMID:16929163 PMID:17440100 PMID:38122923 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G
|
Bcl2l11
|
Bcl2-like 11
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of BCL2L11 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068
|
|
G
|
Bcl6
|
BCL6, transcription repressor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of BCL6 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:76,854,090...76,877,389
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of BDNF protein
|
CTD |
PMID:20531411 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G
|
Bid
|
BH3 interacting domain death agonist
|
increases cleavage
|
ISO
|
Gemcitabine results in increased cleavage of BID protein
|
CTD |
PMID:14750167 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of BIRC2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
multiple interactions affects expression
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC3 protein Gemcitabine affects the expression of BIRC3 mRNA
|
CTD |
PMID:17039268 PMID:17440100 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions decreases expression
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC5 protein Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 protein] Gemcitabine results in decreased expression of BIRC5 protein
|
CTD |
PMID:16929163 PMID:17440100 PMID:38000456 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G
|
Bnip3l
|
BCL2 interacting protein 3 like
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of BNIP3L mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr15:45,350,081...45,373,213
Ensembl chr15:41,174,594...41,197,803
|
|
G
|
Braf
|
B-Raf proto-oncogene, serine/threonine kinase
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of BRAF mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:68,384,649...68,510,463
|
|
G
|
Brca1
|
BRCA1, DNA repair associated
|
decreases response to substance increases expression
|
ISO
|
BRCA1 results in decreased susceptibility to Gemcitabine Gemcitabine results in increased expression of BRCA1 mRNA
|
CTD |
PMID:20103597 PMID:21771338 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions increases activity increases expression
|
ISO
|
Gemcitabine results in increased cleavage of CASP3 protein [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Gemcitabine] affects the activity of CASP3 protein; [3-(4-methylphenylsulfonyl)-2-propenenitrile co-treated with Gemcitabine] affects the activity of CASP3 protein; [alvocidib co-treated with Gemcitabine] results in increased cleavage of CASP3 protein; [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP3 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP3 protein; [Vorinostat co-treated with Gemcitabine] results in increased activity of CASP3 protein; Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein; Gemcitabine results in increased expression of and results in increased activity of CASP3 protein; licoricidin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; licoricidin promotes the reaction [Gemcitabine results in increased expression of and results in increased activity of CASP3 protein]; PIF1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein]; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein] [10-propargyl-10-deazaaminopterin co-treated with Gemcitabine] results in increased activity of CASP3 protein; [Curcumin co-treated with Gemcitabine] results in decreased expression of CASP3 protein Gemcitabine results in increased expression of CASP3 protein modified form
|
CTD |
PMID:12479703 PMID:15476743 PMID:15726400 PMID:15770523 PMID:16153448 PMID:16467107 PMID:17159604 PMID:17440100 PMID:18089714 PMID:20299819 PMID:20699664 PMID:20798217 PMID:21418860 PMID:26050647 PMID:29782821 PMID:37183367 PMID:37704181 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp6
|
caspase 6
|
multiple interactions
|
ISO
|
[Calcitriol co-treated with Gemcitabine] results in increased expression of CASP6 protein
|
CTD |
PMID:20699664 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage increases activity multiple interactions
|
ISO
|
Gemcitabine results in increased cleavage of CASP8 protein Gemcitabine results in increased activity of CASP8 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP8 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP8 protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein; Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]
|
CTD |
PMID:12479703 PMID:14750167 PMID:17159604 PMID:17671697 PMID:18089714 PMID:20699664 PMID:26894857 More...
|
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases cleavage increases activity
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of CASP9 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP9 protein; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP9 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein] Gemcitabine results in increased cleavage of CASP9 protein
|
CTD |
PMID:12479703 PMID:15476743 PMID:15726400 PMID:17159604 PMID:17440100 PMID:20699664 PMID:21418860 PMID:26050647 More...
|
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CCL2 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G
|
Ccl20
|
C-C motif chemokine ligand 20
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CCL20 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:84,388,904...84,391,629
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CCL3 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases expression increases expression
|
ISO
|
Gemcitabine results in decreased expression of CCNB1 mRNA Gemcitabine results in increased expression of CCNB1 protein
|
CTD |
PMID:11504793 PMID:20103597 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions decreases expression
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of CCND1 protein Celecoxib promotes the reaction [Gemcitabine results in decreased expression of CCND1 protein] Gemcitabine results in decreased expression of CCND1 mRNA; Gemcitabine results in decreased expression of CCND1 protein
|
CTD |
PMID:16060994 PMID:17039268 PMID:17440100 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G
|
Ccng2
|
cyclin G2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CCNG2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:15,088,694...15,097,190
Ensembl chr14:14,804,322...14,812,830
|
|
G
|
Cd274
|
CD274 molecule
|
multiple interactions
|
ISO
|
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
|
CTD |
PMID:32894642 |
|
NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:227,116,649...227,134,450
|
|
G
|
Cd40
|
CD40 molecule
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CD40 mRNA; Gemcitabine results in decreased expression of CD40 protein
|
CTD |
PMID:17039268 PMID:20531411 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534
|
|
G
|
Cd40lg
|
CD40 ligand
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CD40LG protein
|
CTD |
PMID:20531411 |
|
NCBI chr X:140,164,341...140,176,057
Ensembl chr X:135,126,969...135,138,306
|
|
G
|
Cd44
|
CD44 molecule
|
affects expression
|
ISO
|
Gemcitabine affects the expression of CD44 mRNA
|
CTD |
PMID:35063459 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620
|
|
G
|
Cda
|
cytidine deaminase
|
affects response to substance multiple interactions
|
ISO
|
CDA protein affects the susceptibility to Gemcitabine [Crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to Gemcitabine; CDA protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]; CDA protein affects the susceptibility to [Gemcitabine co-treated with Oxaliplatin]
|
CTD |
PMID:18728667 PMID:22973962 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
G
|
Cdc25c
|
cell division cycle 25C
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with ON 01910] results in decreased expression of CDC25C protein
|
CTD |
PMID:20103597 |
|
NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,335,834...26,356,185
|
|
G
|
Cdh1
|
cadherin 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CDH1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression multiple interactions
|
ISO
|
Gemcitabine results in increased expression of CDKN1A mRNA; Gemcitabine results in increased expression of CDKN1A protein [alvocidib co-treated with Gemcitabine] results in increased expression of CDKN1A protein; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of CDKN1A protein; Nicotine inhibits the reaction [Gemcitabine results in increased expression of CDKN1A protein]
|
CTD |
PMID:15476743 PMID:15770523 PMID:16601104 PMID:17039268 PMID:25189999 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
decreases response to substance
|
ISO
|
CDKN1B results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:21652059 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CEBPB mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G
|
Chrdl2
|
chordin-like 2
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein
|
CTD |
PMID:24979617 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G
|
Ckb
|
creatine kinase B
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CKB mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:130,729,423...130,732,315
|
|
G
|
Clic4
|
chloride intracellular channel 4
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CLIC4 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
|
|
G
|
Clu
|
clusterin
|
increases expression affects response to substance
|
ISO
|
Gemcitabine results in increased expression of CLU protein CLU protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:19007378 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315
|
|
G
|
Cnr1
|
cannabinoid receptor 1
|
multiple interactions increases expression
|
ISO
|
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]
|
CTD |
PMID:21525939 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G
|
Cnr2
|
cannabinoid receptor 2
|
multiple interactions increases expression
|
ISO
|
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]
|
CTD |
PMID:21525939 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
decreases expression multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of COL1A1 protein Gemcitabine inhibits the reaction [Niclosamide results in decreased expression of COL1A1 protein]; Niclosamide inhibits the reaction [Gemcitabine results in decreased expression of COL1A1 protein]
|
CTD |
PMID:35115509 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G
|
Csf2
|
colony stimulating factor 2
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CSF2 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G
|
Csf3
|
colony stimulating factor 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CSF3 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603
|
|
G
|
Csrp2
|
cysteine and glycine-rich protein 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CSRP2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745
|
|
G
|
Cthrc1
|
collagen triple helix repeat containing 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CTHRC1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
|
|
G
|
Ctnnb1
|
catenin beta 1
|
increases expression decreases expression
|
ISO
|
Gemcitabine results in increased expression of CTNNB1 mRNA Gemcitabine results in decreased expression of CTNNB1 protein
|
CTD |
PMID:25605917 PMID:38000456 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CXCL1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G
|
Cxcl11
|
C-X-C motif chemokine ligand 11
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein
|
CTD |
PMID:24979617 |
|
NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,689,424...15,692,271
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CXCL2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of CXCL1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
affects expression
|
ISO
|
Gemcitabine affects the expression of CXCR4 mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883
|
|
G
|
Cyp24a1
|
cytochrome P450, family 24, subfamily a, polypeptide 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of CYP24A1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:159,275,947...159,290,383
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
affects expression
|
ISO
|
Gemcitabine affects the expression of DDIT4 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G
|
Dhx9
|
DExH-box helicase 9
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of DHX9 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr13:68,152,813...68,189,580
Ensembl chr13:65,602,323...65,639,069
|
|
G
|
Dlg2
|
discs large MAGUK scaffold protein 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of DLG2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G
|
Dnmt1
|
DNA methyltransferase 1
|
multiple interactions
|
ISO
|
[DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; DNMT1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
|
CTD |
PMID:25189999 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:19,440,611...19,486,659
|
|
G
|
Dnmt3b
|
DNA methyltransferase 3 beta
|
multiple interactions
|
ISO
|
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT3B protein
|
CTD |
PMID:25189999 |
|
NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:142,130,592...142,169,124
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
multiple interactions
|
ISO
|
[TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine
|
CTD |
PMID:18728667 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G
|
Dync1h1
|
dynein cytoplasmic 1 heavy chain 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of DYNC1H1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:135,436,375...135,502,117
Ensembl chr 6:129,609,397...129,680,883
|
|
G
|
Edn1
|
endothelin 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of EDN1 protein
|
CTD |
PMID:20531411 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G
|
Edn2
|
endothelin 2
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of EDN2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G
|
Egf
|
epidermal growth factor
|
multiple interactions decreases expression
|
ISO
|
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]] Gemcitabine results in decreased expression of EGF protein
|
CTD |
PMID:20531411 PMID:21613822 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions increases degradation increases phosphorylation increases expression decreases expression
|
ISO
|
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gemcitabine promotes the reaction [HER3 protein binds to EGFR protein] Gemcitabine results in increased degradation of EGFR protein Gemcitabine results in increased phosphorylation of EGFR protein Gemcitabine results in increased expression of EGFR mRNA Gemcitabine results in decreased expression of EGFR mRNA; Gemcitabine results in decreased expression of EGFR protein
|
CTD |
PMID:17146438 PMID:20103597 PMID:20726858 PMID:21541241 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G
|
Egr1
|
early growth response 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of EGR1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
multiple interactions increases phosphorylation
|
ISO
|
Gemcitabine promotes the reaction [HER3 protein binds to EGFR protein] Gemcitabine results in increased phosphorylation of HER3 protein
|
CTD |
PMID:20726858 |
|
NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:996,225...1,015,525
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
Gemcitabine binds to and results in decreased activity of ESR1 protein
|
CTD |
PMID:25752796 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G
|
Etv1
|
ETS variant transcription factor 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ETV1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
|
|
G
|
Evi2b
|
ecotropic viral integration site 2B
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of EVI2B mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
|
|
G
|
F7
|
coagulation factor VII
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of F7 protein
|
CTD |
PMID:20531411 |
|
NCBI chr16:83,191,896...83,202,775
Ensembl chr16:76,489,717...76,500,610
|
|
G
|
Fas
|
Fas cell surface death receptor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of FAS mRNA; Gemcitabine results in increased expression of FAS protein
|
CTD |
PMID:11138460 PMID:17159604 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G
|
Fbxo25
|
F-box protein 25
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of FBXO25 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr16:75,666,062...75,701,770
Ensembl chr16:75,667,904...75,701,696
|
|
G
|
Fgf2
|
fibroblast growth factor 2
|
increases expression multiple interactions
|
ISO
|
Gemcitabine results in increased expression of FGF2 protein [Gemcitabine co-treated with IFNA2 protein] results in increased expression of FGF2 protein
|
CTD |
PMID:12738744 PMID:20531411 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G
|
Fgg
|
fibrinogen gamma chain
|
affects expression
|
ISO
|
Gemcitabine affects the expression of FGG mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:168,355,013...168,362,322
|
|
G
|
Fosl2
|
FOS like 2, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of FOSL2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:24,300,956...24,320,034
|
|
G
|
Fxyd3
|
FXYD domain-containing ion transport regulator 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of FXYD3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:86,305,531...86,312,455
|
|
G
|
Gal3st1
|
galactose-3-O-sulfotransferase 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of GAL3ST1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
|
|
G
|
Gas1
|
growth arrest-specific 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of GAS1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr17:4,487,716...4,490,701
|
|
G
|
Gask1b
|
golgi associated kinase 1B
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of GASK1B mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477
|
|
G
|
Gdf15
|
growth differentiation factor 15
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein
|
CTD |
PMID:24979617 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G
|
Gipc1
|
GIPC PDZ domain containing family, member 1
|
affects response to substance
|
ISO
|
GIPC1 affects the susceptibility to Gemcitabine
|
CTD |
PMID:25469510 |
|
NCBI chr19:41,380,125...41,392,078
Ensembl chr19:24,453,123...24,486,997
|
|
G
|
Gli2
|
GLI family zinc finger 2
|
affects expression
|
ISO
|
Gemcitabine affects the expression of GLI2 mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr13:32,499,678...32,716,418
Ensembl chr13:29,946,809...30,163,574
|
|
G
|
Glrx
|
glutaredoxin
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of GLRX mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G
|
Golph3
|
golgi phosphoprotein 3
|
increases response to substance
|
ISO
|
GOLPH3 protein results in increased susceptibility to Gemcitabine
|
CTD |
PMID:38828452 |
|
NCBI chr 2:61,348,030...61,376,051
Ensembl chr 2:61,348,030...61,376,049
|
|
G
|
Gpc3
|
glypican 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of GPC3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:136,789,770...137,157,598
Ensembl chr X:131,868,990...132,236,798
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
increases phosphorylation
|
ISO
|
Gemcitabine results in increased phosphorylation of GSK3B protein
|
CTD |
PMID:16570353 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646
|
|
G
|
Gtf2a1
|
general transcription factor 2A subunit 1
|
affects expression
|
ISO
|
Gemcitabine affects the expression of GTF2A1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:110,488,891...110,521,502
Ensembl chr 6:110,488,931...110,521,511
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression multiple interactions
|
ISO
|
Gemcitabine results in increased expression of H2AX protein; Gemcitabine results in increased expression of H2AX protein modified form PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]; Thymidine inhibits the reaction [PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]]
|
CTD |
PMID:20798217 PMID:37183367 PMID:38000456 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G
|
H4c14
|
H4 clustered histone 14
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of H4C2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:186,520,468...186,520,863
Ensembl chr 2:183,825,994...183,832,048
|
|
G
|
Hdac9
|
histone deacetylase 9
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of HDAC9 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
affects response to substance
|
ISO
|
HIF1A protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:16628086 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
multiple interactions
|
ISO
|
Gemcitabine promotes the reaction [nuciferine results in decreased expression of HMGCR protein]
|
CTD |
PMID:31627466 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression
|
ISO
|
CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA] Gemcitabine results in increased expression of HMOX1 mRNA; Gemcitabine results in increased expression of HMOX1 protein
|
CTD |
PMID:35913601 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G
|
Hoxb2
|
homeobox B2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of HOXB2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr10:81,317,828...81,320,220
Ensembl chr10:81,318,026...81,320,192
|
|
G
|
Hspa1l
|
heat shock protein family A (Hsp70) member 1 like
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of HSPA1L mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,848,843...3,855,571
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of HSPA5 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
decreases expression multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of ICAM1 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of ICAM1 protein
|
CTD |
PMID:17440100 PMID:20531411 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G
|
Ifng
|
interferon gamma
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IFNG protein
|
CTD |
PMID:20531411 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G
|
Igf1r
|
insulin-like growth factor 1 receptor
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IGF1R mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:121,550,743...121,831,777
|
|
G
|
Igfbp3
|
insulin-like growth factor binding protein 3
|
affects expression
|
ISO
|
Gemcitabine affects the expression of IGFBP3 mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G
|
Il10
|
interleukin 10
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IL10 protein
|
CTD |
PMID:20531411 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G
|
Il13
|
interleukin 13
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of IL13 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737
|
|
G
|
Il15
|
interleukin 15
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IL15 protein
|
CTD |
PMID:20531411 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:25,640,251...25,706,820
|
|
G
|
Il16
|
interleukin 16
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of IL16 protein
|
CTD |
PMID:20531411 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G
|
Il1a
|
interleukin 1 alpha
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IL1A protein
|
CTD |
PMID:20531411 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G
|
Il1b
|
interleukin 1 beta
|
decreases expression multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of IL1B protein [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
|
CTD |
PMID:20531411 PMID:32894642 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G
|
Il4
|
interleukin 4
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IL4 protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G
|
Il6
|
interleukin 6
|
increases secretion decreases expression increases expression
|
ISO
|
Gemcitabine results in increased secretion of IL6 protein Gemcitabine results in decreased expression of IL6 protein Gemcitabine results in increased expression of IL6 mRNA
|
CTD |
PMID:17039268 PMID:20531411 PMID:28007550 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Ilk
|
integrin-linked kinase
|
affects response to substance
|
ISO
|
ILK protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:15867245 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G
|
Ins2
|
insulin 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of INS protein
|
CTD |
PMID:20531411 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G
|
Insig1
|
insulin induced gene 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of INSIG1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G
|
Iqgap1
|
IQ motif containing GTPase activating protein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of IQGAP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G
|
Irak2
|
interleukin-1 receptor-associated kinase 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of IRAK2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 4:148,341,704...148,398,211
Ensembl chr 4:146,786,100...146,842,602
|
|
G
|
Irf3
|
interferon regulatory factor 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of IRF3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G
|
Itgav
|
integrin subunit alpha V
|
multiple interactions
|
ISO
|
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
|
CTD |
PMID:20150628 |
|
NCBI chr 3:89,245,382...89,333,512
Ensembl chr 3:68,838,189...68,926,639
|
|
G
|
Itgb6
|
integrin subunit beta 6
|
multiple interactions
|
ISO
|
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
|
CTD |
PMID:20150628 |
|
NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:45,048,044...45,121,671
|
|
G
|
Itsn2
|
intersectin 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ITSN2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
|
|
G
|
Jam3
|
junctional adhesion molecule 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of JAM3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 8:33,767,606...33,828,451
Ensembl chr 8:25,507,057...25,569,355
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
[Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased expression of and results in increased phosphorylation of JUN protein
|
CTD |
PMID:23033007 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G
|
Kctd12
|
potassium channel tetramerization domain containing 12
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of KCTD12 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G
|
Kitlg
|
KIT ligand
|
multiple interactions decreases expression
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein Gemcitabine results in decreased expression of KITLG protein
|
CTD |
PMID:20531411 PMID:24979617 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G
|
Klf8
|
KLF transcription factor 8
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of KLF8 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:17,950,045...18,132,980
Ensembl chr X:17,958,843...18,133,182
|
|
G
|
Krt8
|
keratin 8
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of KRT8 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G
|
Larp4b
|
La ribonucleoprotein 4B
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of LARP4B mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr17:61,138,663...61,217,423
Ensembl chr17:61,138,709...61,187,960
|
|
G
|
Lep
|
leptin
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of LEP protein
|
CTD |
PMID:20531411 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G
|
Lifr
|
LIF receptor subunit alpha
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of LIFR mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:56,250,120...56,286,699
|
|
G
|
Lpar6
|
lysophosphatidic acid receptor 6
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of LPAR6 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G
|
Lrrc28
|
leucine rich repeat containing 28
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of LRRC28 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:121,116,833...121,245,805
Ensembl chr 1:121,127,733...121,245,784
|
|
G
|
Lta
|
lymphotoxin alpha
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of LTA protein
|
CTD |
PMID:20531411 |
|
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
|
|
G
|
Lyz2
|
lysozyme 2
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of LYZ mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:52,906,811...52,912,106
|
|
G
|
Maf
|
MAF bZIP transcription factor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MAF mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr19:60,259,200...60,622,145
Ensembl chr19:43,360,342...43,712,365
|
|
G
|
Magea10
|
MAGE family member A10
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of MAGEA10 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:150,212,708...150,217,954
Ensembl chr X:150,213,245...150,214,213
|
|
G
|
Magi1
|
membrane associated guanylate kinase, WW and PDZ domain containing 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MAGI1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
|
|
G
|
Map2k3
|
mitogen activated protein kinase kinase 3
|
increases phosphorylation
|
ISO
|
Gemcitabine results in increased phosphorylation of MAP2K3 protein
|
CTD |
PMID:15003513 |
|
NCBI chr10:46,107,639...46,128,986
Ensembl chr10:45,607,163...45,629,492
|
|
G
|
Map2k6
|
mitogen-activated protein kinase kinase 6
|
increases phosphorylation
|
ISO
|
Gemcitabine results in increased phosphorylation of MAP2K6 protein
|
CTD |
PMID:15003513 |
|
NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,373,204...95,488,293
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Gemcitabine results in increased phosphorylation of MAPK1 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:15476743 PMID:23033007 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Gemcitabine results in increased phosphorylation of MAPK3 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:15476743 PMID:23033007 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G
|
Marcks
|
myristoylated alanine rich protein kinase C substrate
|
increases expression increases phosphorylation
|
ISO
|
Gemcitabine results in increased expression of MARCKS mRNA Gemcitabine results in increased phosphorylation of MARCKS protein
|
CTD |
PMID:9523737 PMID:17039268 |
|
NCBI chr20:42,240,185...42,245,882
Ensembl chr20:40,685,315...40,691,012
|
|
G
|
Mars1
|
methionyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MARS1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression decreases expression
|
ISO
|
Gemcitabine results in increased expression of MDM2 mRNA Gemcitabine results in decreased expression of MDM2 mRNA
|
CTD |
PMID:17039268 PMID:20103597 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of MGMT mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G
|
Mir222
|
microRNA 222
|
affects response to substance
|
ISO
|
MIR222 mRNA affects the susceptibility to Gemcitabine
|
CTD |
PMID:35974258 |
|
NCBI chr X:6,022,621...6,022,723
Ensembl chr X:3,428,904...3,429,006
|
|
G
|
Mir24-2
|
microRNA 24-2
|
multiple interactions
|
ISO
|
MIR24-2 mRNA affects the susceptibility to [Betulinic Acid co-treated with Gemcitabine]
|
CTD |
PMID:25841339 |
|
NCBI chr19:23,954,683...23,954,790
Ensembl chr19:23,954,683...23,954,790
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
multiple interactions decreases expression
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of MKI67 protein Gemcitabine results in decreased expression of MKI67 protein
|
CTD |
PMID:17440100 PMID:38000456 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G
|
Mmp3
|
matrix metallopeptidase 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of MMP3 protein
|
CTD |
PMID:20531411 |
|
NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:4,640,416...4,653,961
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with IFNA2 protein] results in increased expression of MMP9 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of MMP9 protein
|
CTD |
PMID:12738744 PMID:17440100 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G
|
Mpo
|
myeloperoxidase
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MPO protein
|
CTD |
PMID:20531411 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G
|
Msh6
|
mutS homolog 6
|
affects response to substance
|
ISO
|
MSH6 protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:39168426 |
|
NCBI chr 6:12,316,190...12,333,505
Ensembl chr 6:6,562,632...6,579,956
|
|
G
|
Msln
|
mesothelin
|
multiple interactions
|
EXP
|
Gemcitabine results in decreased expression of and results in decreased secretion of MSLN protein alternative form
|
CTD |
PMID:25347530 |
|
NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643
|
|
G
|
Mt-co3
|
mitochondrially encoded cytochrome c oxidase III
|
multiple interactions decreases response to substance
|
ISO
|
Sodium Azide inhibits the reaction [COX3 protein results in decreased susceptibility to Gemcitabine]
|
CTD |
PMID:17428446 |
|
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G
|
Mxi1
|
MAX interactor 1, dimerization protein
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MXI1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:262,329,274...262,389,037
Ensembl chr 1:252,323,303...252,383,681
|
|
G
|
Myb
|
MYB proto-oncogene, transcription factor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of MYB mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:15,939,761...15,973,057
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions affects response to substance
|
ISO
|
[Oligonucleotides binds to MYC gene] which results in increased susceptibility to Gemcitabine MYC affects the susceptibility to Gemcitabine [Curcumin co-treated with Gemcitabine] results in decreased expression of MYC protein
|
CTD |
PMID:17440100 PMID:23681918 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G
|
Nanog
|
Nanog homeobox
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of NANOG mRNA
|
CTD |
PMID:25605917 PMID:35063459 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:155,943,737...155,951,116
|
|
G
|
Ncbp1
|
nuclear cap binding protein subunit 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NCBP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089
|
|
G
|
Nedd9
|
neural precursor cell expressed, developmentally down-regulated 9
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NEDD9 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
|
|
G
|
Neu1
|
neuraminidase 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NEU1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
decreases response to substance multiple interactions increases expression
|
ISO
|
NFE2L2 protein results in decreased susceptibility to Gemcitabine CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of CASC9 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA] Gemcitabine results in increased expression of NFE2L2 mRNA; Gemcitabine results in increased expression of NFE2L2 protein
|
CTD |
PMID:21489257 PMID:35913601 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G
|
Nfkb2
|
nuclear factor kappa B subunit 2
|
affects expression
|
ISO
|
Gemcitabine affects the expression of NFKB2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:255,106,010...255,114,649
Ensembl chr 1:245,165,950...245,173,213
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
[Mastic Resin co-treated with Gemcitabine] results in increased expression of NFKBIA protein
|
CTD |
PMID:20523344 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G
|
Nfkbie
|
NFKB inhibitor epsilon
|
affects expression
|
ISO
|
Gemcitabine affects the expression of NFKBIE mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 9:22,941,037...22,947,872
Ensembl chr 9:15,436,941...15,450,437
|
|
G
|
Nnmt
|
nicotinamide N-methyltransferase
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NNMT mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G
|
Notch1
|
notch receptor 1
|
multiple interactions increases expression
|
ISO
|
sulforaphane inhibits the reaction [Gemcitabine results in increased expression of NOTCH1 protein]
|
CTD |
PMID:20940707 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:9,278,086...9,323,531
|
|
G
|
Npepps
|
aminopeptidase puromycin sensitive
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of NPEPPS mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967
|
|
G
|
Npm1
|
nucleophosmin 1
|
decreases response to substance
|
ISO
|
NPM1 protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:24736981 |
|
NCBI chr10:18,245,739...18,255,913
Ensembl chr10:17,739,941...17,751,645 Ensembl chr X:17,739,941...17,751,645
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions increases expression
|
ISO
|
CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA] Gemcitabine results in increased expression of NQO1 mRNA; Gemcitabine results in increased expression of NQO1 protein
|
CTD |
PMID:35913601 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G
|
Nr4a3
|
nuclear receptor subfamily 4, group A, member 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NR4A3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:62,361,822...62,402,733
|
|
G
|
Nrg1
|
neuregulin 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of NRG1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr16:65,954,084...67,007,484
Ensembl chr16:59,250,854...60,296,884
|
|
G
|
Nrp1
|
neuropilin 1
|
decreases response to substance
|
ISO
|
NRP1 protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:15956974 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G
|
Nupr1
|
nuclear protein 1, transcriptional regulator
|
decreases expression affects response to substance
|
ISO
|
Gemcitabine results in decreased expression of NUPR1 mRNA NUPR1 affects the susceptibility to Gemcitabine
|
CTD |
PMID:16397047 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G
|
Or4d6
|
olfactory receptor family 4 subfamily D member 6
|
affects response to substance
|
ISO
|
OR4D6 gene SNP affects the susceptibility to Gemcitabine
|
CTD |
PMID:26378035 |
|
NCBI chr 1:209,039,073...209,040,017
Ensembl chr 1:209,037,992...209,045,985
|
|
G
|
Osm
|
oncostatin M
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein
|
CTD |
PMID:24979617 |
|
NCBI chr14:83,327,202...83,332,073
Ensembl chr14:79,104,344...79,108,313
|
|
G
|
Pappa
|
pappalysin
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of PAPPA protein
|
CTD |
PMID:20531411 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G
|
Paqr8
|
progestin and adipoQ receptor family member 8
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PAQR8 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 9:23,312,521...23,362,175
Ensembl chr 9:23,312,585...23,362,340
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
Gemcitabine results in increased cleavage of PARP1 protein [alvocidib co-treated with Gemcitabine] results in increased cleavage of PARP1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]
|
CTD |
PMID:15770523 PMID:17146438 PMID:26894857 PMID:38122923 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G
|
Parp2
|
poly (ADP-ribose) polymerase 2
|
decreases response to substance
|
ISO
|
PARP2 protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:20798217 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G
|
Pcsk9
|
proprotein convertase subtilisin/kexin type 9
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PCSK9 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G
|
Pdpk1
|
3-phosphoinositide dependent protein kinase-1
|
decreases response to substance
|
ISO
|
PDPK1 protein modified form results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:16782806 |
|
NCBI chr10:13,610,000...13,687,226
Ensembl chr10:13,105,498...13,174,623
|
|
G
|
Pdzk1ip1
|
PDZK1 interacting protein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PDZK1IP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:128,618,050...128,623,131
Ensembl chr 5:128,618,237...128,623,131
|
|
G
|
Pecam1
|
platelet and endothelial cell adhesion molecule 1
|
multiple interactions
|
ISO
|
Gemcitabine promotes the reaction [Curcumin results in decreased expression of PECAM1 protein]
|
CTD |
PMID:17440100 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:91,590,521...91,652,116
|
|
G
|
Pgr
|
progesterone receptor
|
multiple interactions
|
ISO
|
Gemcitabine binds to and results in decreased activity of PGR protein
|
CTD |
PMID:25752796 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G
|
Pif1
|
PIF1 5'-to-3' DNA helicase
|
decreases response to substance multiple interactions affects response to substance
|
ISO
|
PIF1 protein results in decreased susceptibility to Gemcitabine PIF1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP3 protein]; PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]; Thymidine inhibits the reaction [PIF1 protein inhibits the reaction [Gemcitabine results in increased expression of H2AX protein]] PIF1 protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:37183367 |
|
NCBI chr 8:66,110,641...66,120,202
Ensembl chr 8:66,111,072...66,120,200
|
|
G
|
Pja2
|
praja ring finger ubiquitin ligase 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PJA2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
|
|
G
|
Pkm
|
pyruvate kinase M1/2
|
affects response to substance
|
ISO
|
PKM protein alternative form affects the susceptibility to Gemcitabine
|
CTD |
PMID:38000456 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:60,057,402...60,079,599
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PLAU mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G
|
Plk1
|
polo-like kinase 1
|
decreases expression affects response to substance multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of PLK1; Gemcitabine results in decreased expression of PLK1 mRNA PLK1 protein affects the susceptibility to Gemcitabine [Gemcitabine results in decreased expression of PLK1] which results in increased susceptibility to Gemcitabine; ON 01910 promotes the reaction [PLK1 protein affects the susceptibility to Gemcitabine]
|
CTD |
PMID:20103597 |
|
NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:176,716,420...176,726,400
|
|
G
|
Pou5f1
|
POU class 5 homeobox 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of POU5F1 mRNA
|
CTD |
PMID:35063459 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PPARA mRNA
|
CTD |
PMID:19427843 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G
|
Ppard
|
peroxisome proliferator-activated receptor delta
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PPARD mRNA
|
CTD |
PMID:19427843 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,298,785...6,363,968
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PPARG mRNA
|
CTD |
PMID:19427843 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G
|
Ppfia4
|
PTPRF interacting protein alpha 4
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PPFIA4 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr13:45,753,827...45,802,305
Ensembl chr13:45,753,827...45,802,261
|
|
G
|
Ppp1r15a
|
protein phosphatase 1, regulatory subunit 15A
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PPP1R15A mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:96,000,058...96,003,171
|
|
G
|
Psat1
|
phosphoserine aminotransferase 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of PSAT1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G
|
Ptch1
|
patched 1
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PTCH1 mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr17:1,548,449...1,613,461
Ensembl chr17:1,542,877...1,607,333
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PTEN mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of PTGS1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:19,584,015...19,605,586
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
[Curcumin co-treated with Gemcitabine] results in decreased expression of PTGS2 protein
|
CTD |
PMID:17440100 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G
|
Ptk2
|
protein tyrosine kinase 2
|
decreases response to substance
|
ISO
|
PTK2 protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:14623342 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G
|
Ptpn11
|
protein tyrosine phosphatase, non-receptor type 11
|
affects expression
|
ISO
|
Gemcitabine affects the expression of PTPN11 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr12:41,026,079...41,085,577
Ensembl chr12:35,383,144...35,424,925
|
|
G
|
Rab8a
|
RAB8A, member RAS oncogene family
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of RAB8A mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
|
|
G
|
Rbm17
|
RNA binding motif protein 17
|
decreases response to substance
|
ISO
|
RBM17 protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:16061639 |
|
NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014
|
|
G
|
Reg3b
|
regenerating family member 3 beta
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of REG3A mRNA
|
CTD |
PMID:16570353 |
|
NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:110,861,775...110,865,015
|
|
G
|
Rel
|
REL proto-oncogene, NF-kB subunit
|
multiple interactions decreases expression
|
ISO
|
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of REL protein]
|
CTD |
PMID:20940707 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases phosphorylation multiple interactions increases expression
|
ISO
|
Gemcitabine results in increased phosphorylation of RELA protein [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein; [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein; licoricidin inhibits the reaction [Gemcitabine results in increased phosphorylation of RELA protein]; Mastic Resin inhibits the reaction [Gemcitabine results in increased expression of RELA protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of RELA protein
|
CTD |
PMID:17039268 PMID:17440100 PMID:20523344 PMID:29782821 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Rgs2
|
regulator of G-protein signaling 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of RGS2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:55,798,829...55,802,385
|
|
G
|
Rnf149
|
ring finger protein 149
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of RNF149 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 9:41,826,825...41,854,381
Ensembl chr 9:41,830,233...41,854,279
|
|
G
|
Rpl37
|
ribosomal protein L37
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of RPL37 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 2:54,215,469...54,217,429
Ensembl chr 2:54,215,469...54,217,442
|
|
G
|
Rragd
|
Ras-related GTP binding D
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of RRAGD mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356
|
|
G
|
Rrm1
|
ribonucleotide reductase catalytic subunit M1
|
affects response to substance multiple interactions
|
ISO
|
RRM1 protein affects the susceptibility to Gemcitabine [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 protein
|
CTD |
PMID:25189999 PMID:26894857 |
|
NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:156,823,960...156,848,261
|
|
G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
multiple interactions affects response to substance
|
ISO
|
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM2 protein RRM2 protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:25189999 PMID:26894857 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:41,340,557...41,346,773
|
|
G
|
Rsl24d1
|
ribosomal L24 domain containing 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of RSL24D1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 8:73,852,991...73,861,996
Ensembl chr 8:73,852,996...73,862,001
|
|
G
|
Sat1
|
spermidine/spermine N1-acetyl transferase 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SAT1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SCD mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G
|
Sfn
|
stratifin
|
affects response to substance decreases response to substance increases methylation multiple interactions
|
ISO
|
SFN protein affects the susceptibility to Gemcitabine SFN protein results in decreased susceptibility to Gemcitabine Gemcitabine results in increased methylation of SFN gene [DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased methylation of SFN gene; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein promotes the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]
|
CTD |
PMID:25189999 PMID:26894857 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G
|
Shh
|
sonic hedgehog signaling molecule
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of SHH mRNA
|
CTD |
PMID:20103597 |
|
NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:6,954,017...6,963,170
|
|
G
|
Sirt3
|
sirtuin 3
|
decreases expression multiple interactions
|
ISO
|
Gemcitabine results in decreased expression of SIRT3 protein [3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide co-treated with Gemcitabine] results in decreased expression of SIRT3 protein
|
CTD |
PMID:37798514 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G
|
Slc25a29
|
solute carrier family 25 member 29
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SLC25A29 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940
|
|
G
|
Slc28a1
|
solute carrier family 28 member 1
|
multiple interactions
|
EXP ISO
|
Gemcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] Gemcitabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]
|
CTD |
PMID:8713072 PMID:10772724 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G
|
Slc29a1
|
solute carrier family 29 member 1
|
affects response to substance increases response to substance decreases response to substance multiple interactions increases uptake
|
ISO
|
SLC29A1 protein affects the susceptibility to Gemcitabine SLC29A1 mRNA results in increased susceptibility to Gemcitabine; SLC29A1 protein results in increased susceptibility to Gemcitabine SLC29A1 protein results in decreased susceptibility to Gemcitabine 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Gemcitabine]; [S 1 (combination) results in increased expression of SLC29A1 mRNA] which results in increased uptake of Gemcitabine; Fluorouracil promotes the reaction [SLC29A1 protein results in increased uptake of Gemcitabine]
|
CTD |
PMID:15501974 PMID:16868479 PMID:17695509 PMID:18383843 PMID:18452103 PMID:18490900 PMID:18728667 PMID:18992248 PMID:26894857 More...
|
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G
|
Slc29a3
|
solute carrier family 29 member 3
|
affects transport
|
ISO
|
SLC29A3 protein affects the transport of Gemcitabine
|
CTD |
PMID:19164483 |
|
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
|
|
G
|
Slc2a3
|
solute carrier family 2 member 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SLC2A3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:155,960,946...156,025,472
|
|
G
|
Slc43a3
|
solute carrier family 43, member 3
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of SLC43A3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749
|
|
G
|
Slitrk2
|
SLIT and NTRK-like family, member 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SLITRK2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:145,246,448...145,259,983
Ensembl chr X:145,246,460...145,271,220
|
|
G
|
Smg1
|
SMG1, nonsense mediated mRNA decay associated PI3K related kinase
|
decreases response to substance multiple interactions
|
ISO
|
SMG1 protein results in decreased susceptibility to Gemcitabine SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein]
|
CTD |
PMID:21418860 |
|
NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698
|
|
G
|
Smo
|
smoothened, frizzled class receptor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SMO mRNA
|
CTD |
PMID:25605917 |
|
NCBI chr 4:59,311,084...59,341,280
Ensembl chr 4:58,343,529...58,373,829
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SOX2 mRNA
|
CTD |
PMID:25605917 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:117,536,929...117,539,338
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of SPP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
affects response to substance multiple interactions decreases response to substance
|
ISO
|
SRC protein affects the susceptibility to Gemcitabine [AG 1879 co-treated with SRC] results in increased susceptibility to Gemcitabine SRC protein modified form results in decreased susceptibility to Gemcitabine; SRC protein results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:15073106 PMID:15194078 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
decreases activity
|
ISO
|
Gemcitabine results in decreased activity of STAT3 protein
|
CTD |
PMID:22348037 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G
|
Syncrip
|
synaptotagmin binding, cytoplasmic RNA interacting protein
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of SYNCRIP mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G
|
Szrd1
|
SUZ RNA binding domain containing 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of SZRD1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:153,418,748...153,443,286
Ensembl chr 5:153,418,748...153,443,252
|
|
G
|
Tceal9
|
transcription elongation factor A like 9
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TCEAL9 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:99,245,645...99,247,720
Ensembl chr X:99,228,458...99,247,763
|
|
G
|
Tcof1
|
treacle ribosome biogenesis factor 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of TCOF1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324
|
|
G
|
Tert
|
telomerase reverse transcriptase
|
multiple interactions decreases activity
|
ISO
|
[Fluorouracil co-treated with Gemcitabine] results in decreased activity of TERT protein Gemcitabine results in decreased activity of TERT protein
|
CTD |
PMID:16929163 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:29,637,506...29,659,561
|
|
G
|
Tfap2a
|
transcription factor AP-2 alpha
|
increases response to substance multiple interactions
|
ISO
|
TFAP2A protein results in increased susceptibility to Gemcitabine [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine
|
CTD |
PMID:21489314 |
|
NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,024,432...24,047,507
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions decreases response to substance
|
ISO
|
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]
|
CTD |
PMID:21613822 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G
|
Tgfb2
|
transforming growth factor, beta 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TGFB2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:98,160,087...98,261,405
|
|
G
|
Thpo
|
thrombopoietin
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of THPO protein
|
CTD |
PMID:20531411 |
|
Ensembl chr11:80,182,820...80,188,167
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression affects expression
|
ISO
|
Gemcitabine results in increased expression of TNF protein Gemcitabine affects the expression of TNF mRNA
|
CTD |
PMID:17039268 PMID:20531411 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G
|
Tnfaip3
|
TNF alpha induced protein 3
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TNFAIP3 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TNFRSF11B mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:85,566,520...85,594,538
|
|
G
|
Tnfsf10
|
TNF superfamily member 10
|
multiple interactions
|
ISO
|
[TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein
|
CTD |
PMID:17671697 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G
|
Tnfsf8
|
TNF superfamily member 8
|
multiple interactions
|
ISO
|
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein
|
CTD |
PMID:24979617 |
|
NCBI chr 5:82,266,436...82,292,858
Ensembl chr 5:77,251,373...77,277,421
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression affects activity multiple interactions
|
ISO
|
Gemcitabine results in increased expression of TP53 protein Gemcitabine affects the activity of TP53 protein [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine; Nicotine inhibits the reaction [Gemcitabine results in increased expression of TP53 protein]
|
CTD |
PMID:12082016 PMID:16601104 PMID:17671697 PMID:21489314 PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G
|
Tp53bp1
|
tumor protein p53 binding protein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TP53BP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G
|
Tp53inp1
|
tumor protein p53 inducible nuclear protein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TP53INP1 mRNA
|
CTD |
PMID:16570353 PMID:17039268 |
|
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
|
|
G
|
Traf1
|
TNF receptor-associated factor 1
|
affects expression
|
ISO
|
Gemcitabine affects the expression of TRAF1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G
|
Tube1
|
tubulin, epsilon 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of TUBE1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr20:42,552,390...42,570,324
Ensembl chr20:42,552,437...42,570,314
|
|
G
|
Tymp
|
thymidine phosphorylase
|
affects response to substance multiple interactions
|
ISO
|
TYMP protein affects the susceptibility to Gemcitabine [TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine; TYMP protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]
|
CTD |
PMID:18728667 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G
|
Tyrp1
|
tyrosinase-related protein 1
|
affects expression
|
ISO
|
Gemcitabine affects the expression of TYRP1 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:95,280,982...95,299,516
|
|
G
|
Ube2c
|
ubiquitin-conjugating enzyme E2C
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of UBE2C mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:153,506,636...153,513,339
|
|
G
|
Uggt2
|
UDP-glucose glycoprotein glucosyltransferase 2
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of UGGT2 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806
|
|
G
|
Uhrf1
|
ubiquitin-like with PHD and ring finger domains 1
|
multiple interactions
|
ISO
|
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased expression of UHRF1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; UHRF1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
|
CTD |
PMID:25189999 |
|
NCBI chr 9:1,220,162...1,241,792
Ensembl chr 9:1,134,909...1,154,631
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of VCAM1 protein
|
CTD |
PMID:20531411 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression multiple interactions
|
ISO
|
Gemcitabine results in increased expression of VEGFA mRNA [Curcumin co-treated with Gemcitabine] results in decreased expression of VEGFA protein
|
CTD |
PMID:17039268 PMID:17440100 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G
|
Vgf
|
VGF nerve growth factor inducible
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of VGF mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr12:25,274,004...25,281,803
Ensembl chr12:19,637,320...19,640,341
|
|
G
|
Vldlr
|
very low density lipoprotein receptor
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of VLDLR mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
G
|
Vmp1
|
vacuole membrane protein 1
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of VMP1
|
CTD |
PMID:20299819 |
|
NCBI chr10:71,405,058...71,505,045
Ensembl chr10:71,405,452...71,505,007
|
|
G
|
Vwf
|
von Willebrand factor
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of VWF protein
|
CTD |
PMID:20531411 |
|
NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539
|
|
G
|
Wnt5a
|
Wnt family member 5A
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of WNT5A mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,697,032...3,718,234
|
|
G
|
Xbp1
|
X-box binding protein 1
|
multiple interactions
|
ISO
|
Gemcitabine promotes the reaction [1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [arachidonylcyclopropylamide results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [Rimonabant results in increased expression of XBP1 mRNA]
|
CTD |
PMID:21525939 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693
|
|
G
|
Xiap
|
X-linked inhibitor of apoptosis
|
affects response to substance
|
ISO
|
XIAP affects the susceptibility to Gemcitabine
|
CTD |
PMID:16628085 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700
|
|
G
|
Yap1
|
Yes1 associated transcriptional regulator
|
multiple interactions affects response to substance
|
ISO
|
Gemcitabine promotes the reaction [nuciferine results in decreased expression of and results in increased phosphorylation of YAP1 protein]; SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine] YAP1 protein affects the susceptibility to Gemcitabine
|
CTD |
PMID:26894857 PMID:31627466 |
|
NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:5,095,722...5,167,010
|
|
G
|
Zfp110
|
zinc finger protein 110
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ZNF274 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr 1:73,445,303...73,461,112
Ensembl chr 1:73,445,336...73,461,086
|
|
G
|
Zfp449
|
zinc finger protein 449
|
increases expression
|
ISO
|
Gemcitabine results in increased expression of ZNF449 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr X:134,120,820...134,140,921
Ensembl chr X:134,122,636...134,140,924
|
|
G
|
Zfp521
|
zinc finger protein 521
|
decreases expression
|
ISO
|
Gemcitabine results in decreased expression of ZNF521 mRNA
|
CTD |
PMID:17039268 |
|
NCBI chr18:4,775,952...5,068,592
Ensembl chr18:4,787,295...5,068,458
|
|